Cell therapy for lung diseases. Report from an NIH-NHLBI workshop, November 13-14, 2012.

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health convened the Cell Therapy for Lung Disease Working Group on November 13-14, 2012, to review and formulate recommendations for future research directions. The workshop brought together investigators studying basic mechanisms and the roles of cell therapy in preclinical models of lung injury and pulmonary vascular disease, with clinical trial experts in cell therapy for cardiovascular diseases and experts from the NHLBI Production Assistance for Cell Therapy program. The purpose of the workshop was to discuss the current status of basic investigations in lung cell therapy, to identify some of the scientific gaps in current knowledge regarding the potential roles and mechanisms of cell therapy in the treatment of lung diseases, and to develop recommendations to the NHLBI and the research community on scientific priorities and practical steps that would lead to first-in-human trials of lung cell therapy.

[1]  B. Trapnell,et al.  Pulmonary Macrophage Transplantation Therapy , 2014, Nature.

[2]  M. Glassberg,et al.  Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing. , 2013, American journal of respiratory and critical care medicine.

[3]  R. Casaburi,et al.  A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. , 2013, Chest.

[4]  Wendell A. Lim,et al.  Cell-Based Therapeutics: The Next Pillar of Medicine , 2013, Science Translational Medicine.

[5]  Xu Cao,et al.  The meaning, the sense and the significance: translating the science of mesenchymal stem cells into medicine , 2013, Nature Medicine.

[6]  M. Königshoff,et al.  Endogenous lung regeneration: potential and limitations. , 2012, American journal of respiratory and critical care medicine.

[7]  D. Kotton,et al.  Next-generation regeneration: the hope and hype of lung stem cell research. , 2012, American journal of respiratory and critical care medicine.

[8]  Joshua M Hare,et al.  Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. , 2012, JAMA.

[9]  D. Emery,et al.  Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia , 2012, Thorax.

[10]  Changjin Lee,et al.  Exosomes Mediate the Cytoprotective Action of Mesenchymal Stromal Cells on Hypoxia-Induced Pulmonary Hypertension , 2012, Circulation.

[11]  J. Marshall,et al.  Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials , 2012, PloS one.

[12]  M. V. Cromer,et al.  Perspective: Communications with the Food and Drug Administration on the Development Pathway for a Cell‐Based Therapy: Why, What, When, and How? , 2012, Stem cells translational medicine.

[13]  T. Moss,et al.  Cell Therapy: A Novel Treatment Approach for Bronchopulmonary Dysplasia , 2012, Pediatrics.

[14]  Garth M. Beache,et al.  Administration of Cardiac Stem Cells in Patients With Ischemic Cardiomyopathy: The SCIPIO Trial Surgical Aspects and Interim Analysis of Myocardial Function and Viability by Magnetic Resonance , 2012, Circulation.

[15]  D. Stewart,et al.  Genetically modified endothelial progenitor cells in the therapy of cardiovascular disease and pulmonary hypertension. , 2012, Current vascular pharmacology.

[16]  B. Thébaud,et al.  Preconditioning enhances the paracrine effect of mesenchymal stem cells in preventing oxygen-induced neonatal lung injury in rats. , 2012, Stem cells and development.

[17]  D. Rowlands,et al.  Mitochondrial transfer from bone-marrow–derived stromal cells to pulmonary alveoli protects against acute lung injury , 2012, Nature Medicine.

[18]  G. Hansmann,et al.  Mesenchymal stem cell-mediated reversal of bronchopulmonary dysplasia and associated pulmonary hypertension , 2012, Pulmonary circulation.

[19]  E. Ingenito,et al.  Autologous Lung-Derived Mesenchymal Stem Cell Transplantation in Experimental Emphysema , 2012, Cell transplantation.

[20]  Marcus F Stoddard,et al.  Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial , 2011, The Lancet.

[21]  Yusuke Yamamoto,et al.  Distal Airway Stem Cells Yield Alveoli In Vitro and during Lung Regeneration following H1N1 Influenza Infection , 2011, Cell.

[22]  J. Hare,et al.  Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. , 2011, Circulation research.

[23]  Arnoud Sonnenberg,et al.  Integrin α6β4 identifies an adult distal lung epithelial population with regenerative potential in mice. , 2011, The Journal of clinical investigation.

[24]  E. Ingenito,et al.  Lung-derived mesenchymal stromal cell post-transplantation survival, persistence, paracrine expression, and repair of elastase-injured lung. , 2011, Stem cells and development.

[25]  S. Masuda,et al.  Evidence for human lung stem cells. , 2011, The New England journal of medicine.

[26]  D. Warburton,et al.  Stem cells and cell therapies in lung biology and lung diseases. , 2011, Proceedings of the American Thoracic Society.

[27]  P. Pattany,et al.  Bone Marrow Mesenchymal Stem Cells Stimulate Cardiac Stem Cell Proliferation and Differentiation , 2010, Circulation research.

[28]  Christian Schuetz,et al.  Regeneration and orthotopic transplantation of a bioartificial lung , 2010, Nature Medicine.

[29]  Joshua M Hare,et al.  A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. , 2009, Journal of the American College of Cardiology.

[30]  S. Archer,et al.  Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. , 2009, American journal of respiratory and critical care medicine.

[31]  O. Liang,et al.  Bone marrow stromal cells attenuate lung injury in a murine model of neonatal chronic lung disease. , 2009, American journal of respiratory and critical care medicine.

[32]  Scott H. Randell,et al.  Basal cells as stem cells of the mouse trachea and human airway epithelium , 2009, Proceedings of the National Academy of Sciences.

[33]  S. Houser,et al.  Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. , 2009, Blood.

[34]  Darwin J. Prockop,et al.  Mitochondrial transfer between cells can rescue aerobic respiration , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[35]  T. Jacks,et al.  Identification of Bronchioalveolar Stem Cells in Normal Lung and Lung Cancer , 2005, Cell.

[36]  Simon C Watkins,et al.  Basal cells are a multipotent progenitor capable of renewing the bronchial epithelium. , 2004, The American journal of pathology.